中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart

On November 21, 2023, Simcere Pharmaceutical Group Limited (“Simcere”)entered into an exclusive license and collaboration agreement (the “Agreement”) ...

2023-11-21
COSELA® granted full approval by NMPA

COSELA® granted full approval by NMPAOn Oct 30 2023，Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary...

2023-11-07
Simcere Zaimig announces new IND approval of SIM0237, an anti-PD-L1/IL-15 bispecific antibody by NMPA

On Oct 15, 2023, Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group announced ...

2023-10-16
2023 ESMO：Simcere Zaiming will showcase latest clinical data regarding 3 three innovative products and 3 pipeline candidates

COSELA®（Trilaciclib Hydrochloride for Injection ）：2 posters Antitumor Activity and Safety Profile of Trilaciclib in Chinese patients wit...

2023-10-16
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.